宜華健康(000150.SZ):公司控制權終止變更 實控人仍為劉紹喜
格隆匯8月6日丨宜華健康(000150.SZ)公佈,公司於近日收到控股股東宜華企業(集團)有限公司(“宜華集團”)的吿知,獲悉宜華集團與北京新里程健康產業集團有限公司(“新里程健康”)簽署了《表決權委託協議之終止協議》,終止表決權委託事項。
此次表決權委託暨終止公司控制權變更事項不會影響上市公司目前的日常經營狀況和財務情況,不會對上市公司的持續經營產生不利影響,不存在損害廣大投資者特別是中小股東利益的情形。
公司控制權終止變更,控股股東仍為宜華集團,實際控制人仍為劉紹喜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.